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Chun-Nan Yeh1,6, Wen-Hung Chung2,6, Shih-Chi Su2, Yen-Yang Chen3, Chi-Tung Cheng1, Yen-Ling Lin4,
Wan-Chun Chang4, Rosaline Chung-Yee Hui2, Kun-Chun Chiang1, Tsung-Wen Chen1, Yi-Yin Jan1,
Chien-Wei Chen4, Ting-Jui Chen4,5, Chih-Hsun Yang2 and Shuen-Iu Hung4
Sunitinib, a multitargeted receptor Y kinase inhibitor (TKI) used for the treatment of renal cell carcinoma and
gastrointestinal stromal tumor (GIST), is notorious for cutaneous adverse effects, such as hand-foot skin reaction
(HFSR). To explore the underlying mechanism of HFSR, we enrolled 53 sunitinib-treated GIST patients, including
23 HFSR cases, and 30 tolerant controls. Among the 29 biomarkers examined, soluble FasL (sFasL) showed
significant increase in the plasma, blister fluids, and skin lesions of HFSR patients. The plasma levels of sFasL were
significantly correlated with those of sunitinib in HFSR patients. In addition to FasL, augmented expression of Fas
and active caspase 3 was also detected in the epidermis of HFSR patients. The increased FasL caused keratinocyte
death, as the use of anti-FasL antibody specifically blocked cell apoptosis. Oral administration of sunitinib to mice
increased skin susceptibility to mechanical injuries in a dose/time-dependent manner. The administration of
sunitinib (40mgkg 1 per day) for 4 weeks to mice caused the maximally affected skin area with an erosion-
to-ulceration response to tape-stripping. The skin biopsies of mice administered sunitinib exhibited increased
expression of Fas and FasL in the apoptotic keratinocytes in the epidermis. Our data revealed that Fas/FasL
interaction mediates keratinocyte death in sunitinib-induced HFSR.
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INTRODUCTION
Sunitinib is a multitargeted receptor Y kinase inhibitor that is
used for the treatment of metastatic renal cell carcinoma and
imatinib-resistant gastrointestinal stromal tumor (GIST) (Chow
and Eckhardt, 2007). Sunitinib inhibits cellular signaling
of multiple receptor Y kinases, including all receptors for
platelet-derived growth factor (PDGF-Rs), vascular endothelial
growth factor receptors (VEGFRs), KIT (CD117), Fms-like Y
Kinase-3 (FLT3), colony-stimulating factor 1, and RET proto-
oncogene, all of which are involved in a great variety of
malignancies (Gan et al., 2009). Despite their effectiveness
and benefits on the treatment of cancer and survival, sunitinib
and other Y kinase inhibitors (e.g., sorafenib) are notorious for
their relatively high frequency of cutaneous adverse reactions,
including mucositis (up to 20% of patients), rash (up to 40%),
alopecia (up to 27%), xerosis (up to 16%), xerostomia (up to
11%), and hand-foot skin reaction (HFSR) (up to 60%; Adams
and Leggas, 2007; Gan et al., 2009; Manchen et al., 2011;
Nardone et al., 2012).
HFSR, also known as ‘‘palmar plantar erythrodysesthesia’’
or ‘‘chemotherapy-induced acral erythema’’, is characterized
by thick, hyperkeratotic, and erythema/edema lesions with
pain, a loss of feeling, and swelling and redness in the palms
of hands and/or soles of feet, which occurs with chemothera-
pies and emerges with targeted therapies (Lacouture et al.,
2008; Anderson et al., 2009; Lipworth et al., 2009). Although
HFSR is not life threatening, such an adverse reaction is
associated with significant tenderness affecting function and
quality of life, which often leads to dose modification or
discontinuation of treatment (Chu et al., 2007; George et al.,
2009; Lee et al., 2009). Asian patients exhibit increased
susceptibility to Y kinase inhibitor-induced HFSR (Anderson
et al., 2009; George et al., 2009; Lee et al., 2009; Chen et al.,
2011; Lee et al., 2012). Genetic polymorphisms of tumor
necrosis factor-a, VEGF, and UGT1A9 genes have been
reported to link to HFSR in patients of hepatocellular
carcinoma treated with sorafenib (Lee et al., 2013).
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Currently, several hypotheses regarding the pathophysio-
logy of HFSR have been suggested. Sunitinib-induced HFSR
was proposed to be caused by poor repair of repeated small
traumas to the hands and feet due to the inhibition of VEGF
receptors and PDGF receptors, or by direct skin toxicity from
the drug (Cheng et al., 2009). Accumulation of potentially
toxic concentrations of the causative drug in eccrine sweat
glands, which are present in greatest number or density in the
palms and soles may lead to a direct cytotoxicity against acral
epithelium in HFSR (Mrozek-Orlowski et al., 1999; Jacobi
et al., 2005). In addition, damaged vascular integrity and
keratinocyte injury may have an impact on HFSR induced by
anti-angiogenic agents (Tsai et al., 2006; Lacouture et al.,
2008). Such theory is supported by the association of VEGF
polymorphisms with high-grade HFSR in patients with
hepatocellular carcinoma after sorafenib therapy (Lee et al.,
2013). Others proposed a more mechanical mechanism in
which VEGF inhibition and direct pressure from walking, hand
washing, and other daily use combine to damage capillary
endothelium and cause the skin damage and blistering
observed in HFSR (Tsai et al., 2006). To explore the
molecular mechanism of HFSR, in this study, we recruited
53 sunitinib-treated GIST patients, and analyzed potential
biomarkers.
RESULTS
Elevated plasma levels of sunitinib in patients with HFSR
We enrolled 53 GIST patients (32 males, 21 females) who
were imatinib resistant, and then received sunitinib treatment.
Patients were followed up after sunitinib administration at
regular intervals (median follow-up time: 13.9 months). The
adverse reactions induced by sunitinib in GIST patients
included diarrhea, mucositis/stomatitis, hypertension, HFSR,
rash, and skin discoloration, out of which HFSR was the most
common (Table 1). Among 53 GIST patients, 23 (43.4%)
developed grade 1–3 HFSR, and the remaining 30 subjects
without HFSR were considered as sunitinib-tolerant controls
(Table 1). We observed that HFSR usually occurred in the
palms or soles of patients who have received the oral
administration of sunitinib (37.5B50 mg per person per day)
for 4–8 weeks, which is consistent with the previous reports
(Lacouture et al., 2008; Yang et al., 2010). We obtained
plasma samples of 17 HFSR patients at the acute stage and 24
tolerant controls at steady-state after 4 weeks of daily dosing.
The plasma levels of sunitinib were significantly increased
in HFSR patients (mean±SD: 85.8±27.3 ng ml1; range:
52.9–130.2) than those of tolerant controls (53.4±14.5ngml1;
19.7–87.1; P¼ 0.008; Figure 1a), suggesting the poor metabolism
and delayed clearance of sunitinib in HFSR patients.
Elevated FasL levels in the plasma and blister fluids of HFSR
patients
We examined the plasma levels of 29 potential biomarkers,
including 27 cytokines, and 2 cytotoxic proteins (FasL and
granulysin) in HFSR patients, tolerant controls, and healthy
donors (Figure 1b, Supplementary Figure S1 online). Among
the tested factors, soluble Fas ligand (sFasL) showed the most
significant increase in the plasma of HFSR patients (mean±
SEM: 119.8±21.0 pg ml1) compared with tolerant controls
(50.4±4.2 pg ml1; P¼ 0.0048) and healthy donors (53.2±
3.7 pg ml 1; P¼ 0.0065) (Figure 1b). No significant difference
in the plasma levels of other cytokines, such as IL-6 and tumor
necrosis factor-a-a, was detected between HFSR patients
and tolerant controls (Supplementary Figure S1a online). Of
note, the level of granulysin, a cytotoxic protein identified as a
key mediator of keratinocyte death in Stevens–Johnson syn-
drome and toxic epidermal necrolysis (Chung et al., 2008;
Krensky and Clayberger, 2009), showed no difference bet-
ween HFSR and controls (Supplementary Figure S1b online).
The FasL levels in the blister fluids were significantly
increased in the HFSR patients (n¼3; mean±SEM: 133.2±
18.98 pg ml1) compared with those in burn patients (n¼ 10;
67.73±10.55 pg ml1; P¼0.0216; Figure 1c). Furthermore,
the plasma levels of FasL were correlated with sunitinib
(n¼ 17, r¼ 0.56, P¼0.019; Figure 1d). These results suggest
that FasL may be a biomarker of sunitinib-induced HFSR.
Elevated expression of Fas, FasL, and cleaved caspase 3 in the
skin lesions of HFSR patients
The histopathological analyses of HFSR skin biopsies showed
hyperkeratosis, acanthosis, and intraepidermal cavities filled
with necrotic keratinocytes (Figure 2, Supplementary Figures
S2 and S3 online). In addition, loss of keratinocyte cohesion
and keratinocyte necrosis was observed at the level of
the stratum spinosum/granulosum (Figure 2, Supplementary
Figures S2 and S3 online). Compared with the skin samples of
healthy donors, increased expression of FasL, Fas receptor,
and cleaved caspase 3 was noticed in the keratinocytes
around the intraepidermal areas of HFSR (Figure 2, Supple-
mentary Figures S2 and S3 online). Staining with isotype
control antibodies showed no immunereactivity in the skin
biopsies (Supplementary Figure S3 online). These results reveal
the increased expression of Fas, FasL, and active caspase 3 in
the keratinocytes of the epidermis in the skin lesions of HFSR.
FasL mediates the cytotoxicity of HFSR plasma to keratinocyte
cultures
To investigate FasL-mediated cytotoxicity in HFSR, we cul-
tured human keratinocytes with 10% plasma from HFSR
Table 1. Adverse events of sunitinib-treated GIST
patients
Variable
Sunitinib (n¼53)
Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Diarrhea 9 (17.0%) 13 (24.5%) 0 0
Mucositis/stomatitis 8 (15.1%) 1(1.9%) 1 (1.9%) 0
Hypertension 5 (9.4%) 9 (17.0%) 5 (9.4%) 0
Hand-foot skin reaction 5 (9.4%) 9 (17.0%) 9 (17.0%) 0
Rash 4 (7.5%) 4 (7.5%) 0 0
Skin discoloration 8 (15.1%) 0 0 0
Abbreviation: GIST, gastrointestinal stromal tumor.
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patients (n¼ 5), healthy donors (n¼ 5), or 10% fetal bovine
serum (medium control) for 24 hours and analyzed the
cytotoxicity by the CCK-8 assay. The plasma from HFSR
patients significantly induced cytotoxicity to keratinocytes in
comparison with the medium control or plasma from healthy
subjects (Figure 3a). The increased cytotoxicity was abolished
by the anti-FasL antibody (5G51) that could interfere with Fas/
FasL interaction (Collins et al., 2005); however, unaffected by
isotype control antibody (Figure 3a). To further assess FasL-
mediated keratinocyte apoptosis in HFSR, we incubated
keratinocytes with 10% plasma from HFSR patients (n¼5)
for 6 hours and stained annexin V. Compared with the
medium control or plasma from healthy donors, an augmen-
ted apoptotic response was observed in the keratinocytes
treated with 10% plasma of HFSR patients (Figure 3b and c).
This apoptotic response is specifically diminished by anti-FasL
antibody, but not the isotype control antibody (Figure 3b
and c), suggesting that FasL mediates keratinocyte apoptosis in
HFSR.
Oral administration of sunitinib to mice increased the skin
susceptibility to mechanical injuries
Anticancer therapy–induced HFSR has been proposed to
involve the combined effects of direct pressure to the affected
areas and drug toxicity (Tsai et al., 2006). To develop an
animal model of HFSR, we orally administered different doses
of sunitinib (0, 20, 40 mg kg1 per day) to mice for various
time periods (1, 2, and 4 weeks) and evaluated the skin
response to tape-stripping. The tape-stripping method allowed
us to induce a mechanical disruption of the epidermal barrier
and concurrently study the effect of sunitinib on skin with
mechanical injuries. The expression of Fas/FasL was then
examined in the back skin with tape-stripping and in the foot
pads without tape stripping. In the absence of tape-stripping,
no apparent skin injuries or HFSR was found in the mice
administered the maximal dose (40 mg kg1 per day) of
sunitinib (Figure 4) for 4 weeks. With tape stripping, the mice
showed increased susceptibility to mechanical pressure in a
sunitinib dose/time-dependent manner (Figure 4). Significant
increase of the affected area was found in mice administered
sunitinib at 40 mg kg1 per day for 2 weeks (P¼ 0.0043),
20 mg kg1 per day for 4 weeks (P¼ 0.0087), or 40 mg kg 1
per day for 4 weeks (P¼0.0022; Figure 4). In particular, the
mice receiving sunitinib (40 mg kg1 per day) for 4 weeks
showed the maximally affected skin areas with an erosion-
to-ulceration response to tape-stripping application (Figure 4).
Sunitinib increased the expression of Fas/FasL in the
keratinocytes of the epidermis in mice
The skin biopsies of mice were obtained and subjected to
hematoxylin and eosin (H&E) staining and immunohistochem-
istry studies. The in vivo efficacy of sunitinib was demon-
strated by a decreased level of phosphor-PDGFR (p-PDGFR) in
the subcorneal epidermis of foot pads of treated mice (Supple-
mentary Figure S4 online). H&E staining of affected skin
samples showed epidermal acanthosis with erosions or ulcers
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Figure 1. Elevated levels of sunitinib and FasL in the plasma and blister fluids of sunitinib-induced HFSR patients. The plasma levels of sunitinib (a) and sFasL
(b) were analyzed by high-performance liquid chromatographic or ELISA in the samples of tolerant controls (tolerance; n¼14), sunitinib-induced HFSR
patients (n¼ 17), and the healthy donors (HD; n¼ 10). (c) The FasL levels in the blister fluids (BF) of burn patients (n¼10) and HFSR patients (n¼3) were
measured by ELISA. (d) Correlation of plasma levels of FasL and sunitinib in the HFSR patients (n¼17, r¼ 0.56, P¼0.019). Data are presented as mean±SEM.
*Po0.05; **Po0.01.
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Figure 2. Increased expression of FasL, Fas, and cleaved caspase 3 in the skin lesions of HFSR patients. Skin biopsies were obtained from an affected area
in the sole of a patient with grade 3 hand-foot skin reaction (HFSR) or a healthy donor. The skin sections were stained by hematoxylin and eosin, or specific
antibodies against FasL, Fas, or active caspase 3. The basement membrane was indicated by a dotted line, and locations of epidermis (E) and dermis (D) were
noted. The marked areas were shown in high magnification, in which the increased expression of Fas, FasL, and caspase 3 was noticed around apoptotic
keratinocytes within epidermis in the skin biopsies of HFSR. Photographs of one representative HFSR case are shown. Left panels, bar¼100mm; central
panels, bar¼ 200mm; right panels, bar¼ 20mm.
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Figure 3. FasL mediates the cytotoxicity of HFSR plasma to keratinocytes. Keratinocytes (HaCaT cells) were cultured in the medium containing 10% fetal
bovine serum, 10% plasma from healthy donors (HD; n¼ 5), 10% plasma from hand-foot skin reaction (HFSR) patients (n¼5), or 10% HFSR plasma preincubated
with an anti-FasL antibody (5G51) or an isotype control antibody. Cytotoxicity (a) and apoptosis (b) were analyzed by the CCK-8 assay after a 24-hour incubation
and by annexin V staining after a 6-hour incubation, respectively. The assays were performed in triplicate, and data are presented as mean±SD. **Po0.01;
***Po0.001. (c) Photographs depicting the early-stage apoptosis of human keratinocytes stained with annexin V (FITC green fluorescence). The blue color
represented 4’,6-diamidino-2-phenylindole-stained nuclei of cells. Bar¼ 50mm.
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in mice given sunitinib (40 mg kg1 per day, 4 weeks) and
tape-stripping application (Figure 5). Furthermore, the epider-
mis of the foot pads of mice treated with sunitinib showed
increased dyskeratosis in H&E staining, although there was no
gross change observed (Figure 5). By immunohistochemistry
staining, we found that sunitinib-treated mice showed strong
expression of Fas/FasL in the ulcerated epidermis of tape-
stripped back skin (Figure 5). Consistently, the increased
expression of Fas/FasL was also detected in the epidermis of
foot pads of sunitinib-treated mice (Figure 5). In contrast, no
or only weak expression of Fas/FasL was observed in the
epidermis of vehicle controls (Figure 5). These data further
support that Fas/FasL interaction is involved in keratinocyte
death in sunitinib-induced HFSR.
DISCUSSION
This study revealed the increased expression of sunitinib and
FasL in the plasma of HFSR patients, and their concentrations
showed strong correlation. The plasma of HFSR patients
caused keratinocyte death, and such cytotoxicity could be
blocked specifically by an anti-FasL antibody. Oral adminis-
tration of sunitinib to mice increased the skin susceptibility
to mechanical pressure. Mice administered sunitinib at
40 mg kg1 per day for 4 weeks showed the maximally
affected skin area with erosion-to-ulceration response to
tape-stripping application. Furthermore, increased expression
of FasL, Fas, and active caspase 3 was detected in the
epidermis of skin lesions in HFSR patients as well as in the
tape-stripped skin or foot pads of mice treated with sunitinib.
These findings suggest a pathogenic role of Fas/FasL interac-
tion in keratinocyte death in sunitinib-induced HFSR, and
shed light on the molecular mechanism of HFSR.
The Fas/FasL system is a key molecular regulator of
apoptosis. There is evidence revealing that dysregulation of
FasL expression and/or signaling contributes to the pathogen-
esis of various cutaneous diseases, such as toxic epidermal
necrolysis (Viard et al., 1998; Viard-Leveugle et al., 2013),
fixed drug eruption (Choi et al., 2006), acute graft versus host
disease (Baker et al., 1996), maculopapular rashes (Wang
et al., 2011), lichenoid dermatoses (Farley et al., 2011), and
Behcet’s syndrome (Baris et al., 2005). In addition, FasL
signaling has been shown to be functional in human
keratinocytes (Sayama et al., 1994). Under basal conditions,
keratinocyte FasL is expressed at very low levels and is
not cytolytic because of its intracellular localization
(Viard-Leveugle et al., 2003). Upon appropriate stimulation,
however, keratinocyte FasL can be induced to become lytic to
cells (Gutierrez-Steil et al., 1998).
Through screening 29 various cytokines and cytotoxic
proteins, we identified a significant elevation of sFasL in the
plasma of HFSR patients. The increase of sFasL does not seem
to be derived from peripheral blood mononuclear cells as
there was no difference in the expression level of FasL in
peripheral blood mononuclear cells from sunitinib-induced
HFSR and tolerant controls (Supplementary Figure S5 online).
In addition, the plasma sFasL was not contributed by the
cancer tissues, as no increased expression of FasL was
detected in GIST cell lines or tumor specimens after sunitinib
treatment (Supplementary Figure S6 online). Our histological
data showing keratinocyte apoptosis accompanied with the
increased Fas and FasL expression in the epidermis of HFSR
patients and the mouse model imply that elevated sFasL
detected in the plasma, in part, may result from cleavage of a
membrane-bound FasL on the keratinocytes of HFSR patients.
It is intriguing that sunitinib treatment made the skin more
susceptible to physical damage and such injury was associated
with increased expression of FasL in keratinocytes. We
observed the strong correlation between the plasma levels of
sunitinib and FasL in HFSR patients. The direct cytotoxicity of
FasL on the keratinocytes and colocalization of FasL, Fas, and
active caspase 3 in the epidermis of HFSR patients and
sunitinib-treated mouse models indicate the pathogenic role
of sFasL in HFSR. Moreover, the increased mouse suscept-
ibility to mechanical injury and induction of keratinocyte
FasL/Fas in the animal experiments further support the com-
bined effects of sunitinib toxicity and physical pressures in
HFSR. Further studies are needed to investigate how poor
metabolism of Y kinase inhibitors and mechanical/physical
pressure interplay with Fas/FasL signaling and cause keratino-
cyte death in HFSR.
In addition to a key player of apoptosis, different functions
of FasL in regulation of cell activation and angiogenesis have
been proposed (Alderson et al., 1993; Biancone et al., 1997).
Furthermore, Fas/FasL interactions have been suggested to be
proinflammatory, because Fas signaling results in the activa-
tion of caspases that cleave and activate the proinflammatory
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cytokines (Restifo, 2000). Also, it has been documented that
FasL production, in particular membrane-bound FasL, is
effectively linked to inflammation (Hohlbaum et al., 2000).
In this regard, the Fas/FasL system may also be potentially
implicated in the inflammation in HFSR along with apoptosis.
This suggests that the dysregulation of the FasL signaling
pathway may not only contribute to the apoptosis of
keratinocytes but also likely promote the following inflam-
matory responses, leading to the extensive skin damage
in HFSR.
In conclusion, this study demonstrated that the increased
FasL expression may trigger keratinocyte apoptosis in HFSR
caused by sunitinib treatment, indicating a pathogenic role for
Fas/FasL signaling in HFSR. Our findings provide insights into
the molecular basis of HFSR and may shed additional light on
the development of better management techniques for HFSR.
MATERIALS AND METHODS
Study participants
From 2006 to 2012, we recruited 53 patients with immunohistolo-
gically confirmed metastatic GIST, who were treated with sunitinib at
Chang Gung Memorial Hospital (CGMH), Taiwan. This study was
conducted according to the Declaration of Helsinki Principles, and
approved by the institutional review board of CGMH. Written
informed consent was obtained from each participant. Patients were
administered 50 mg (4 weeks on, 2 weeks off) or 37.5 mg (continu-
ously) of sunitinib in 12.5 mg capsules taken orally daily with food.
The toxic effects were recorded in accordance with the National
Cancer Institute Common Toxicity Criteria. Blister cells/fluids were
obtained from patients with grade 3 HFSR or from subjects with burn
injuries. Plasma samples were obtained from the acute stage of HFSR
patients, or at the end of a 4-week administration of daily dosing
sunitinib in tolerant controls. The plasma levels of sunitinib were
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determined by the high-performance liquid chromatographic method
(Blanchet et al., 2009).
ELISA and Bio-Plex
The expression levels of 27 cytokines, granulysin, and FasL in the
plasma samples or blister fluids were measured using the Bio-Plex Pro
Human Cytokine 27-plex Assay (Bio-Rad Laboratories, Hercules, CA)
or ELISA (R&D Systems, Minneapolis, MN). The 27 cytokines include
IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70),
IL-13, IL-15, IL-17, basic fibroblast growth factor, eotaxin, G-CSF,
GM-CSF, IFN-g, IP-10, MCP-1 (MCAF), MIP-1a, MIP-1b, PDGF-BB,
RANTES, tumor necrosis factor-a-a, and VEGF.
Animal study protocol
The Experimental Animal Ethics Committee of the institute approved
the animal protocols of this study. This investigation conformed to the
US National Institute of Health (NIH) guidelines for the care and use
of laboratory animals (Publication No. 85-23, revised 1996). To
establish an animal model of HFSR, we orally administered different
doses of sunitinib (0, 20, 40 mg kg 1 per day) to C3H/HeJ mice
(4-week-old females) for various time periods (1, 2, and 4 weeks). The
animals were randomized into nine groups (each group, n¼ 6): three
vehicle groups without sunitinib administration serving the controls
of 1, 2, and 4 weeks, and six groups receiving sunitinib daily
(20 mg kg 1 per day or 40 mg kg 1 per day) for 1, 2, and 4 weeks
by oral gavage. The backs of mice were shaved to observe the skin
change. To create mechanical pressure on the mouse skin, we
adapted the previously published method (Sano et al., 2005) and
performed tape stripping using 20 strokes with transparent tape on the
dorsal skin every day for 4 days from the fourth day of the 1st, 2nd,
and 4th week. Images were taken before and after tape stripping, and
tissues were collected after the course of procedure. At the 7th day of
the 1st, 2nd, and 4th week, the animals were anesthetized using
pentobarbital (15 mg kg 1, intraperitoneally), and the back skin and
foot pads were excised and fixed in 4% paraformaldehyde for
histopathological and immunohistochemical analyses. The
photographs of skin injuries were analyzed by Bernsen’s auto local
thresholding method v1.4 using ImageJ 1.47 m. The skin injury was
calculated as the ratio of the wound area to the tape-stripped area and
expressed as the percentage of the affected area.
Histopathological and immunohistochemical staining
Mice. H&E staining and immunohistochemical analyses were
performed on snap-frozen, OCT Tissue-Tek (Sakura Finetek,
Torrance, CA) cryoprotectant-embedded, paraformaldehyde-fixed
mouse skin tissue. For immunohistochemical staining, the slides
of skin tissues from the back or foot pads were incubated with the
primary antibodies against FasL (#ab68338, Abcam, Cambridge,
MA), Fas (#ab82419, Abcam), or phospho-PDGF Receptor b
(Tyr1021) (#ab16868, Abcam) overnight at 4 1C, washed three
times for 5 min in tris-buffered saline with tween 20, and
incubated with the secondary antibody before visualization with
the DAKO LSAB2 system peroxidase (DAKO A/S, No K0675,
Carpentaria, CA). The control slides were incubated with the
secondary antibody, or isotype control antibodies alone.
Patients. Skin specimens were obtained from the affected area of
foot of patients with grade 3 HFSR or healthy subjects and stained
with H&E. The specimens were stained with primary antibodies
(1:200 dilution) against FasL (NCL-Fas-L, Leica Biosystems, St
Louis, MO), Fas (NCL-FAS-310, Leica Biosystems), or cleaved
caspase 3 (#9664S, Cell Signaling, Danvers, MA) overnight at
4 1C. The control slides were incubated with the secondary
antibody or isotype control antibodies and then washed three
times (5 min each) in tris-buffered saline with tween 20 and
incubated with the secondary antibody before visualization using
the DAKO LSAB2 system peroxidase (DAKO A/S, Copenhagen,
Denmark, No K0675). After washing, the slides were mounted
and microscopically analyzed by the investigators, who were
unaware of the source of the slides.
Cell culture and cytotoxicity assay
HaCaT human keratinocytes were obtained from ATCC. HaCaT cells
were cultured in DMEM in 96-well plates at the density of 2 104
cells per well with 10% plasma from sunitinib-induced HFSR patient,
10% plasma from healthy donors, or 10% fetal bovine serum. For
blocking the Fas/FasL interaction, a FasL antibody (ALX-804-231-
C100, clone: 5G51, Enzo Life Sciences, Farmingdale, NY) or isotype
control (6602872, Beckman Coulter, Brea, CA) was added to the
culture medium with a final concentration of 0.5mg ml 1 for 1 hour
at 37 1C before the incubation with keratinocytes. After 24 hours of
incubation, the cell viability was analyzed by the cell counting kit-8
(CCK-8 assay, Sigma, St Louis, MO).
Annexin V staining
HaCaT cells were incubated on collagen-coated 8-well chamber slides
(Nunc, Thermo Scientific, Waltham, MA) at a density of 4 104 cells
per well overnight and treated with the indicated conditions for
6 hours. After the treatment, cells were washed by phosphate-buffered
saline, fixed with 4% paraformaldehyde, and then incubated with anti-
annexin V-FITC (eBioscience, San Diego, CA) and 4’,6-diamidino-2-
phenylindole (Sigma). For immunofluorescence imaging, photographs
were taken under a Nikon (Tokyo, Japan) Eclipse TE2000U fluores-
cence inverted microscope equipped with a CCD camera and
MetaMorph software (Universal Imaging, Bedford Hills, NY). Apoptotic
response was calculated as the ratio of the number of cells immunos-
tained for membrane annexin V to the total number ;of nuclei per field
and expressed as the percentage of annexin V–positive cells.
Statistical analysis
All statistical analyses were performed using the SPSS computer
software package (Version 10.0, Chicago, IL). The expression levels of
FasL and biomarkers in different groups were compared by nonpara-
metric tests. The plasma levels of sunitinib in HFSR patients or
tolerant controls were analyzed by the Mann–Whitney U-test. Linear
regression was applied to analyze the correlation of plasma levels of
FasL and sunitinib in the HFSR patients. All of the P-values were two-
tailed, and a P-value ofo0.05 was considered statistically significant.
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